Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05549921Phase 2Unknown

Phase II Study of TAEST16001 in Soft Tissue Sarcoma

Role: collaborator

NCT03462316Phase 1Unknown

NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

Role: collaborator

NCT04318964Phase 1Unknown

TAEST16001 in the Treatment of Soft Tissue Sarcoma

Role: collaborator

NCT03159585Phase 1Completed

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors

Role: collaborator

NCT03029273Phase 1Unknown

NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC

Role: collaborator

All 5 trials loaded